122 related articles for article (PubMed ID: 1516794)
21. [VCAP therapy of multiple myeloma].
Umeda M; Kaneko H; Katoh M; Yamaguchi R; Masaki T; Ishikawa I; Yamauchi M; Kiga Y; Hara A; Nojima Z
Rinsho Ketsueki; 1987 Jul; 28(7):1147-51. PubMed ID: 3694822
[No Abstract] [Full Text] [Related]
22. The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test.
Baccouche H; Hadhri M; Aissi W; Chakroun A; Bahri D; Mahjoub S; Ben Romdhane N
Int J Lab Hematol; 2019 Oct; 41(5):684-690. PubMed ID: 31421013
[TBL] [Abstract][Full Text] [Related]
23. [Multiple myeloma: therapeutic response to 2 modalities of chemotherapy].
Lira P; Walker B; Grebe G
Rev Med Chil; 1986 May; 114(5):436-40. PubMed ID: 3589221
[No Abstract] [Full Text] [Related]
24. [Pitfalls in the diagnosis and course of Kahler's disease].
Lokhorst HM; Dekker AW
Ned Tijdschr Geneeskd; 1987 Jun; 131(26):1105-7. PubMed ID: 3614391
[No Abstract] [Full Text] [Related]
25. Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma.
Monconduit M; Le Loet X; Bernard JF; Michaux JL
Br J Haematol; 1986 Jul; 63(3):599-601. PubMed ID: 3730288
[No Abstract] [Full Text] [Related]
26. [Comparative evaluation of the effectiveness of mono- and polychemotherapy programs in patients with multiple myeloma].
Abdulkadyrov KM; Bessmel'tsev SS
Klin Med (Mosk); 1992; 70(9-10):57-60. PubMed ID: 1474818
[No Abstract] [Full Text] [Related]
27. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
[TBL] [Abstract][Full Text] [Related]
28. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
[No Abstract] [Full Text] [Related]
29. Multiple myeloma in Korea--clinical analysis and treatment results in 61 cases.
Kim HJ; Heo DS; Bang YJ; Lee SJ; Choi DH; Park SY; Kim BK; Kim NK; Heo M; Lee M
Korean J Intern Med; 1987 Jan; 2(1):120-4. PubMed ID: 3154811
[TBL] [Abstract][Full Text] [Related]
30. Alpha-interferon combination therapy of resistant myeloma.
Alexanian R; Barlogie B; Gutterman J
Am J Clin Oncol; 1991 Jun; 14(3):188-92. PubMed ID: 2031504
[TBL] [Abstract][Full Text] [Related]
31. [Current aspects of treatment of multiple myeloma].
Tribalto M; Avvisati G; Cantonetti M; Catalano G; Giovangrossi P; Masi M; Petrucci MT; Venditti A; Papa G
Ann Ital Med Int; 1988; 3(3):193-202. PubMed ID: 3152856
[No Abstract] [Full Text] [Related]
32. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Hussain MJ; Robinson MM; Hamadeh I; Arnall J; Bhutani M; Atrash S; Friend R; Pineda-Roman M; Symanowski JT; Usmani SZ; Voorhees PM
Br J Haematol; 2019 Jul; 186(1):140-144. PubMed ID: 30536372
[No Abstract] [Full Text] [Related]
33. [Bortezomib-based regimen for the treatment of 110 multiple myeloma patients].
Yang GZ; Chen WM
Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(38):2671-4. PubMed ID: 21162894
[TBL] [Abstract][Full Text] [Related]
34. Multiple myeloma presenting as Sjogren's syndrome.
Fadilah SA; Cheong SK
Am J Hematol; 1999 Jul; 61(3):217-8. PubMed ID: 10398318
[No Abstract] [Full Text] [Related]
35. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis.
van Marion AM; Auwerda JJ; Minnema MC; van Oosterom R; Adelmeijer J; de Groot PG; Leebeek FW; Sonneveld P; Lokhorst HM; Lisman T
Thromb Haemost; 2005 Dec; 94(6):1341-3. PubMed ID: 16411420
[No Abstract] [Full Text] [Related]
36. Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome.
Sridhar S; Dutta TK; Basu D
J Indian Med Assoc; 2011 Dec; 109(12):880-2, 887-8. PubMed ID: 23469567
[TBL] [Abstract][Full Text] [Related]
37. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
He Q; Zhao X; He Y; Tan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
[TBL] [Abstract][Full Text] [Related]
38. [Monochemotherapy and polychemotherapy of multiple myeloma].
Kraj M; Maj S; Rostkowska J; Pogłód R; Słomkowski M
Nowotwory; 1984; 34(1):65-75. PubMed ID: 6377239
[No Abstract] [Full Text] [Related]
39. Rate of M-component changes and clinical course of 23 responsive myeloma patients.
Riccardi A; Montecucco C; Merlini G; Cremonini N; Danova M; Ascari E
Haematologica; 1984; 69(3):305-14. PubMed ID: 6432642
[No Abstract] [Full Text] [Related]
40. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Lemaire O; Attal M; Bourin P; Laroche M
Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
